Conestoga Capital Advisors LLC Has $109.56 Million Stock Position in Transcat, Inc. (NASDAQ:TRNS)

Conestoga Capital Advisors LLC lifted its position in Transcat, Inc. (NASDAQ:TRNS - Free Report) by 17.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 907,191 shares of the scientific and technical instruments company's stock after acquiring an additional 137,830 shares during the period. Transcat accounts for approximately 1.5% of Conestoga Capital Advisors LLC's investment portfolio, making the stock its 25th biggest holding. Conestoga Capital Advisors LLC owned about 9.91% of Transcat worth $109,561,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of TRNS. US Bancorp DE increased its stake in Transcat by 15.6% during the 3rd quarter. US Bancorp DE now owns 1,547 shares of the scientific and technical instruments company's stock worth $187,000 after buying an additional 209 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Transcat by 28.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 79,303 shares of the scientific and technical instruments company's stock worth $9,577,000 after purchasing an additional 17,743 shares during the last quarter. Arkadios Wealth Advisors lifted its stake in Transcat by 38.7% during the third quarter. Arkadios Wealth Advisors now owns 6,118 shares of the scientific and technical instruments company's stock worth $739,000 after purchasing an additional 1,707 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in Transcat by 16,241.2% during the 3rd quarter. International Assets Investment Management LLC now owns 2,778 shares of the scientific and technical instruments company's stock valued at $335,000 after acquiring an additional 2,761 shares during the period. Finally, Raymond James & Associates grew its holdings in shares of Transcat by 157.2% in the third quarter. Raymond James & Associates now owns 20,651 shares of the scientific and technical instruments company's stock valued at $2,494,000 after purchasing an additional 12,622 shares in the last quarter. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Transcat Trading Down 0.2 %

NASDAQ:TRNS traded down $0.16 during midday trading on Friday, hitting $95.41. 120,824 shares of the stock were exchanged, compared to its average volume of 53,096. The company has a market capitalization of $873.00 million, a price-to-earnings ratio of 48.27 and a beta of 0.67. The business has a 50-day moving average price of $122.34 and a two-hundred day moving average price of $121.99. Transcat, Inc. has a one year low of $84.45 and a one year high of $147.12.

Transcat (NASDAQ:TRNS - Get Free Report) last released its quarterly earnings results on Monday, October 28th. The scientific and technical instruments company reported $0.35 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.47 by ($0.12). The firm had revenue of $67.83 million for the quarter, compared to analyst estimates of $70.30 million. Transcat had a net margin of 6.63% and a return on equity of 7.62%. The firm's revenue was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.41 EPS. Sell-side analysts forecast that Transcat, Inc. will post 2.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on TRNS shares. StockNews.com downgraded shares of Transcat from a "hold" rating to a "sell" rating in a research note on Tuesday. Craig Hallum decreased their target price on shares of Transcat from $138.00 to $113.00 and set a "buy" rating for the company in a research note on Wednesday. HC Wainwright restated a "buy" rating and set a $156.00 price objective on shares of Transcat in a research report on Tuesday. Northland Securities dropped their price objective on Transcat from $130.00 to $110.00 and set a "market perform" rating on the stock in a report on Wednesday. Finally, Oppenheimer reiterated an "outperform" rating and set a $130.00 price target (down from $155.00) on shares of Transcat in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $127.25.

Transcat Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.